

<b>Notice of References Cited</b>		Application/Control No. 10/763,424	Applicant(s)/Patent Under Reexamination KARLIK ET AL.	
		Examiner Maher M. Haddad	Art Unit 1644	Page 1 of 1

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

#### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)			
*	U	Polman et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899-910.			
*	V	Munschauer et al Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability. Abstract P474, World on Treatment and research in multiple sclerosis, september 17-20, 2008, montreal, Canada.			
	W	National Horizon Scanning Centre: New and Emerging Technology Briefing-Natalizumab for Multiple Sclerosis. July 2002, pages 1-5.			
	X	Tubridy et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 1999 Aug 11;53(3):466-72			

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(e).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.